Medicare Enrolled
Dr. Youssef Hanna, MD
Hematology & Oncology · Port Huron, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hanna from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hanna?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hanna
Dr. Youssef Hanna is a hematology & oncology specialist in Port Huron, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Hanna performed 48,825 Medicare services across 1,444 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hanna received a total of $4,568 from 45 pharmaceutical and/or device companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hanna is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 11% volume in MI
$4,568 industry payments
Medicare Practice Summary
Medicare Utilization ↗48,825
Medicare services
Top 11% in MI for hematology & oncology
1,444
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,441 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
29,070 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 8,400 | $43 | $107 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
3,600 | $0 | $4 |
| Denosumab injection (Prolia/Xgeva) | 1,980 | $18 | $44 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,155 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 990 | $1 | $39 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
760 | $8 | $20 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
360 | $21 | $80 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
298 | $93 | $155 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
291 | $61 | $160 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
270 | $8 | $15 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
241 | $97 | $306 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
216 | $79 | $364 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
163 | $11 | $66 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
159 | $10 | $52 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
148 | $2 | $6 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
124 | $1 | $5 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
82 | $48 | $190 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
68 | $46 | $199 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
56 | $1 | $3 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
51 | $21 | $58 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
46 | $36 | $108 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
44 | $1 | $5 |
| New patient office visit, complex (60-74 min) | 32 | $168 | $442 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
31 | $42 | $182 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
31 | $65 | $153 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
29 | $140 | $352 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
27 | $2 | $6 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
21 | $94 | $219 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
19 | $121 | $351 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
18 | $14 | $52 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
17 | $19 | $73 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
14 | $60 | $271 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
14 | $144 | $425 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
61.1% high complexity
34.8% medium
4.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,568
Total received (2018-2024)
Avg $653/year across 7 years
Top 30% in MI for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
208
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,229 (92.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$339 (7.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$805
2023
$861
2022
$570
2021
$684
2020
$316
2019
$696
2018
$637
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$170
ABBVIE INC.
$116
Novartis Pharmaceuticals Corporation
$114
Ethicon Inc.
$101
PFIZER INC.
$76
GlaxoSmithKline, LLC.
$40
Mirati Therapeutics, Inc.
$36
Janssen Biotech, Inc.
$34
Celgene Corporation
$32
Kite Pharma, Inc.
$25
Octapharma USA, Inc.
$23
ARRAY BIOPHARMA INC
$19
Gilead Sciences, Inc.
$18
Top 3 companies account for 49.9% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$619
PFIZER INC.
$410
AstraZeneca Pharmaceuticals LP
$325
E.R. Squibb & Sons, L.L.C.
$314
Amgen Inc.
$214
Janssen Biotech, Inc.
$212
Exelixis Inc.
$203
AMAG Pharmaceuticals, Inc.
$172
ABBVIE INC.
$141
GlaxoSmithKline, LLC.
$125
Regeneron Healthcare Solutions, Inc.
$125
Ipsen Biopharmaceuticals, Inc
$118
Pharmacyclics LLC, An AbbVie Company
$115
Takeda Pharmaceuticals U.S.A., Inc.
$104
AbbVie Inc.
$103
Ethicon Inc.
$101
Mirati Therapeutics, Inc.
$92
Genentech USA, Inc.
$91
Seagen Inc.
$88
Gilead Sciences, Inc.
$85
Merck Sharp & Dohme Corporation
$84
GENZYME CORPORATION
$72
Incyte Corporation
$59
ARRAY BIOPHARMA INC
$55
Celgene Corporation
$55
Deciphera Pharmaceuticals Inc.
$47
EMD Serono, Inc.
$44
Medtronic, Inc.
$37
Puma Biotechnology, Inc.
$34
TESARO, Inc.
$34
Astellas Pharma US Inc
$32
Merck Sharp & Dohme LLC
$27
Kite Pharma, Inc.
$25
Eisai Inc.
$24
Octapharma USA, Inc.
$23
TOLMAR Pharmaceuticals, Inc.
$22
Taiho Oncology, Inc.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$17
Sumitomo Pharma America, Inc.
$16
SERVIER PHARMACEUTICALS LLC
$15
AbbVie, Inc.
$15
Janssen Pharmaceuticals, Inc
$14
Novo Nordisk Inc
$13
AVEO Pharmaceuticals, Inc.
$13
Aveo Pharmaceuticals, Inc.
$12
Top 3 companies account for 29.6% of all-time payments
Associated products mentioned in payments ›
Alecensa · Avastin · BLENREP · BRAFTOVI · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · CREON · Cabometyx · Creon · DARZALEX · ELIGARD · ELIQUIS · ERLEADA · FERAHEME · FOTIVDA · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · Monarch Platform · NERLYNX · NINLARO · Neulasta · NovoSeven RT · OJJAARA · OPDIVO · ORGOVYX · Onivyde · PADCEV · PANZYGA · PIQRAY · PROMACTA · Pomalyst · QINLOCK · REBLOZYL · SHINGRIX · SPRYCEL · SUTENT · TAGRISSO · TALZENNA · TECVAYLI · TUKYSA · TURBOHAWK · Tibsovo · Trodelvy · VENCLEXTA · Vectibix · XALKORI · XARELTO · XTANDI · Xospata · Yescarta · ZEJULA · ZEPOSIA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
3
Per 100K population
1.9
County median income
$69,349
Nearest hospital
LAKE HURON MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Hanna is a mixed practice specialist, with above-average Medicare volume (top 11% in MI), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Hanna experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Hanna performed 29,070 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hanna receive payments from pharmaceutical companies?
Yes. Dr. Hanna received a total of $4,568 from 45 companies across 208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hanna's costs compare to other hematology & oncology specialists in Port Huron?
Dr. Hanna's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hanna) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Port Huron
Browse hematology & oncology specialists in Port Huron ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MI
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MI
Which MI hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology